LAE-001 is under clinical development by Laekna Therapeutics Shanghai and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase II drugs for Hormone-Sensitive Prostate Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LAE-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LAE-001 overview
LAE-001 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). The drug candidate is administered through oral route in the form of capsule. It acts by targeting CYP17A and CYP11B2.
It was also under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Laekna Therapeutics Shanghai overview
Laekna Therapeutics Shanghai, a subsidiary of Laekna Inc, is a biotechnology company engaged in research and development of novel therapies for the treatment of liver fibrosis, cancer and metabolic diseases. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of LAE-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
